Biomarker · Gene alteration

FLT3 mutation (ITD / TKD)

FLT3 internal tandem duplications or tyrosine kinase domain point mutations detected by PCR fragment analysis or sequencing of blood or marrow; used as a predictive marker for FLT3 inhibitors and a prognostic marker in acute myeloid leukemia.

CI-BIO-00000046FLT3 graph →NCIt C128919

Also calledFLT3-ITD · FLT3-TKD · FLT3 internal tandem duplication · FLT3-mutated · D835

Derived

Associated cancers (8)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Acute Myeloid Leukemia	70	49	19	2	3 / 30 / 4 / 33 / 0
Acute Promyelocytic Leukemia	2	1	1	—	0 / 2 / 0 / 0 / 0
Adult B Acute Lymphoblastic Leukemia	1	1	—	—	0 / 0 / 1 / 0 / 0
Leukemia	1	1	—	—	0 / 0 / 0 / 1 / 0
Malignant Colorectal Neoplasm

Derived

Drugs with predictive evidence (24)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
SorafenibSmall Molecule	12	5	7	B	4 / 8	Acute Myeloid Leukemia, Leukemia
SunitinibSmall Molecule	10	8	1	B	5 / 1	Acute Myeloid Leukemia,

Curated evidence

Predictive evidence items (55)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 51–55 of 55 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FLT3 Overexpression1
Sunitinib

Regulatory

Approvals mentioning the linked drugs (133)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE INJECTION (DIN 02515296) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 21, 2022	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as VYXEOS (DIN 02515490) under ATC L01XY01 CYTARABINE AND DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 6, 2021	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as PMS-CYTARABINE (DIN 02406772) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 16, 2014	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as PMS-CYTARABINE (DIN 02406764) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Jul 31, 2024	Jan 16, 2014	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as DEPOCYT (DIN 02241150) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jun 29, 2017	Dec 29, 2000	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE INJECTION (DIN 02126656) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 23, 1996	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE - PWS 2GM/VIAL (DIN 02167891) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 26, 2015	Dec 31, 1995	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE - PWS 1GN/VIAL (DIN 02167883) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 26, 2015	Dec 31, 1995	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE - PWS 500MG/VIAL (DIN 02167875) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Oct 26, 2015	Dec 31, 1995	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE-PWS 100MG/VIAL (DIN 02167867) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince May 7, 2018	Dec 31, 1995	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE INJ 100MG/ML (DIN 00885797) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Aug 13, 1998	Dec 31, 1992	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 00646296) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 4, 2025	Dec 31, 1986	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 00646318) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 4, 2025	Dec 31, 1986	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 00194727) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 4, 2025	Dec 31, 1977	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 00386715) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 4, 2025	Dec 31, 1977	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as AJ-CYTARABINE (DIN 02404397) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Nov 3, 2015	—	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 02403838) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE INJECTION, MYLAN STD. (DIN 02402203) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Feb 24, 2022	—	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTARABINE INJECTION BP (DIN 02394901) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Aug 1, 2019	—	health-canada-dpd
Cytarabine	CA Health Canada	—	Marketed in Canada as CYTOSAR (DIN 02403811) under ATC L01BC01 CYTARABINE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as DAUNORUBICIN INJECTABLE SOLUTION (DIN 02501481) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 2, 2026	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as DAUNORUBICIN HYDROCHLORIDE INJECTION (DIN 02539209) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 31, 2024	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as VYXEOS (DIN 02515490) under ATC L01XY01 CYTARABINE AND DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 6, 2021	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as DAUNORUBICIN HYDROCHLORIDE FOR INJECTION (DIN 02231420) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Apr 30, 2018	Mar 4, 1998	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as DAUNOXOME LIPOSOMAL - IV 2MG/ML, 50MG/VIAL (DIN 02218046) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 21, 2001	Sep 22, 1997	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as CERUBIDINE (DIN 01926683) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1971	health-canada-dpd
Daunorubicin	CA Health Canada	—	Marketed in Canada as DAUNORUBICIN INJECTABLE SOLUTION (DIN 02501473) under ATC L01DB02 DAUNORUBICIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Gilteritinib	CA Health Canada	—	Marketed in Canada as XOSPATA (DIN 02495058) under ATC L01EX13 GILTERITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 3, 2020	health-canada-dpd
Midostaurin	CA Health Canada	—	Marketed in Canada as RYDAPT (DIN 02466236) under ATC L01EX10 MIDOSTAURIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 8, 2017	health-canada-dpd
Ponatinib	CA Health Canada	—	Marketed in Canada as ICLUSIG (DIN 02437341) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Dormantsince Aug 8, 2022	Jan 7, 2016	health-canada-dpd
Ponatinib	CA Health Canada	—	Marketed in Canada as ICLUSIG (DIN 02437333) under ATC L01EA05 PONATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 21, 2015	health-canada-dpd
Quizartinib	CA Health Canada	—	Marketed in Canada as VANFLYTA (DIN 02558378) under ATC L01EX11 QUIZARTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 30, 2026	health-canada-dpd
Quizartinib	CA Health Canada	—	Marketed in Canada as VANFLYTA (DIN 02558351) under ATC L01EX11 QUIZARTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 30, 2025	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530147) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO (DIN 02530139) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 3, 2023	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO GRANULES (DIN 02569736) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Selumetinib	CA Health Canada	—	Marketed in Canada as KOSELUGO GRANULES (DIN 02569744) under ATC L01EE04 SELUMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sorafenib	CA Health Canada	—	Marketed in Canada as NEXAVAR (DIN 02284227) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2006	health-canada-dpd
Sorafenib	CA Health Canada	—	Marketed in Canada as APO-SORAFENIB (DIN 02490641) under ATC L01EX02 SORAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552892) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02552906) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as NAT-SUNITINIB (DIN 02539284) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 30, 2025	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532190) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 18, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526212) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as TEVA-SUNITINIB (DIN 02526204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 11, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532204) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 21, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as AURO-SUNITINIB (DIN 02532220) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 21, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532867) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 24, 2023	health-canada-dpd
Sunitinib	CA Health Canada	—	Marketed in Canada as SANDOZ SUNITINIB (DIN 02532840) under ATC L01EX01 SUNITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 24, 2023	health-canada-dpd

Associated cancers (8)

Drugs with predictive evidence (24)

Predictive evidence items (55)

Approvals mentioning the linked drugs (133)

Active trials (148)

Linked publications (46)